Search

The author discusses a study of the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA) known as Molly or Ecstasy as potential therapeutics for severe post-traumatic stress disorder (PTSD) conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS). MDMA was developed in a research on blood-clotting agents in 1912, used in psychotherapy in the 1970s, and emerged as a recreational drug in the 1980s. It describes the preparation of participants for the study.

The article focuses on the perioperative management of cats suffering from high-rise syndrome, which involves treating cats that have fallen from significant heights The article emphasizes the need for thorough evaluation, trauma-specific interventions, and an understanding of potential complications, such as systemic inflammatory response syndrome (SIRS), coagulopathies, and multiorgan dysfunction, commonly seen in traumatized cats and effective pain management.

A report from I.M. Sechenov First Moscow State Medical University discusses the findings of a study on thrombotic microangiopathies (TMA). TMA refers to a group of disorders characterized by blood clotting in small blood vessels, leading to organ damage. The study highlights the role of thrombo-inflammation in TMA pathogenesis and identifies various causes and pathophysiology for different syndromes within TMA. The research emphasizes the importance of prompt diagnosis and treatment in managing TMA and preventing serious complications. Treatment involves identifying the underlying cause, inhibiting complement activation, and providing supportive care. Plasmapheresis may be beneficial in certain conditions like thrombotic thrombocytopenic purpura (TTP). [Extracted from the article]

A clinical trial is currently recruiting participants in Egypt to study the use of romiplostim, a thrombopoietin receptor agonist, in children with chronic immune thrombocytopenic purpura (ITP) who do not respond to steroids. ITP is an autoimmune disease characterized by low platelet count and purpura caused by antiplatelet autoantibodies. The trial aims to assess the short-term efficacy and safety of romiplostim, with the most commonly reported drug-related adverse effects being headache, nausea, and hepatobiliary laboratory abnormalities. The trial will enroll 100 participants and will exclude patients with other causes of thrombocytopenia, chronic disease, acute ITP, and newly diagnosed ITP. [Extracted from the article]

A report from the University College London (UCL) Hospitals NHS Foundation Trust discusses the use of caplacizumab in pediatric immune thrombotic thrombocytopenic purpura (TTP). TTP is a rare and potentially life-threatening disease in children. The study retrospectively described the use of caplacizumab in 16 patients under 18 years of age, including 4 children under 12 years old. The results showed that caplacizumab was effective and safe in the pediatric population, reducing the need for plasma exchange compared to previous treatments. This research has implications for the management and duration of hospital admission for pediatric TTP patients. [Extracted from the article]

A recent study conducted by researchers at the University of Toronto has found that caplacizumab, a medication used to treat immune-mediated thrombotic thrombocytopenic purpura (iTTP), improves clinical outcomes and is well tolerated across diverse patient subgroups. The study analyzed data from the phase 3 HERCULES study and categorized patients based on their prior iTTP history, disease severity at presentation, and initial immunosuppression regimen. The results showed that caplacizumab led to a shorter time to platelet count response and reduced the risk of iTTP-related complications compared to a placebo. The findings highlight the need for treatments with rapid onset of action to reduce mortality and complications associated with iTTP. [Extracted from the article]

A new report discusses research findings on sepsis-related liver injury (SALI) in Northeast China. The study found that SALI occurs in about a third of septic patients and is often a poor prognostic factor. The researchers explored the clinical characteristics, risk factors, and prognosis of early SALI in 201 patients with confirmed sepsis. They identified high aspartate transaminase (AST), high direct bilirubin, and low plasma thromboplastin antecedent (PTA) as risk factors for sepsis with SALI. The study concluded that septic patients with early SALI have early-onset coagulation disorders that require early intervention, and elevated AST, PTA, and direct bilirubin may be independent risk markers of sepsis-related liver injury. [Extracted from the article]

The article discusses recent findings from the Icahn School of Medicine at Mount Sinai on the effectiveness of viscoelastic hemostatic assays in managing postpartum hemorrhage and guiding blood transfusion decisions. Topics discussed include the role of these assays in detecting coagulation defects, their advantages over traditional transfusion approaches, and their application in treating inherited or acquired coagulation disorders.

The article presents a case study of a 41-year-old patient exhibited symptoms of thyroid storm including palpitations and heat intolerance, which progressed to acute liver failure with hepatic encephalopathy and coagulopathy. Despite standard management of thyroid storm, the patient developed DIC and eventually died. The study highlights the importance of recognizing these rare complications and underscores the need for advanced therapeutic strategies in severe cases.

The article examines a study from the Mayo Clinic analyzing the seasonal distribution of immune thrombotic thrombocytopenic purpura (iTTP) across multiple centers worldwide. Topics include the significant correlation between iTTP episodes and colder temperatures, particularly in regions farther from the equator, and potential implications for future therapies.

A recent study conducted at the University of Minnesota examined the association between antithrombin III deficiency and outcomes among patients with trauma. Antithrombin III is a plasma protein that regulates coagulation. The study found that patients with antithrombin III deficiency had more severe injuries, increased hemorrhage, and higher mortality rates. They also had fewer ventilator-free, hospital-free, and ICU-free days. These findings suggest that antithrombin III levels may be useful in assessing the risk of patients with trauma. [Extracted from the article]

A case study from Zhejiang University in Jinhua, People's Republic of China, explores the treatment of a case of congenital thrombotic thrombocytopenic purpura (TTP) induced by pregnancy complicated with cerebral vasospasm. The study found that plasma transfusion therapy led to a transient occurrence of cerebral vasospasm. The researchers emphasize the importance of careful consideration when administering plasma transfusions in congenital TTP during pregnancy and suggest the development of novel therapeutic approaches. This research has been peer-reviewed and published in Clinical Laboratory. [Extracted from the article]

A case report and literature review from Geneva University Hospitals discusses the use of caplacizumab as an add-on therapy in a 7-year-old girl with immune-mediated thrombotic thrombocytopenic purpura (iTTP). iTTP is typically treated with therapeutic plasma exchange, corticosteroids, and rituximab, but the use of caplacizumab in children under 12 years old is not well-established. In this case, the patient showed a positive response to caplacizumab, with an increase in platelet count and a complete recovery. The study suggests that further research is needed to support the use of caplacizumab in this age group. [Extracted from the article]

A recent report discusses research on thrombocytopenic purpura, a condition characterized by low platelet count. The report focuses on a case study of a 45-year-old Chinese female with Sjogren's syndrome (SS), immune-mediated thrombotic thrombocytopenic purpura (ITTP), and posterior reversible encephalopathy syndrome (PRES). The patient's clinical data and treatment procedure are discussed, and the report concludes that plasma exchange and immunosuppressive therapy should be administered immediately after a suspected or confirmed diagnosis of ITTP. The researchers also suggest that rituximab may have additional therapeutic value for SS combined with ITTP and PRES. [Extracted from the article]

A recent study conducted at Tel Aviv University in Israel explored the atypical presentations of pediatric-acquired thrombotic thrombocytopenic purpura (iTTP), a rare and severe blood disorder. The study examined the medical files of four children diagnosed with iTTP and found a variety of presentations, including primary iTTP, iTTP induced by Shiga toxin, iTTP associated with RAS-associated autoimmune leukoproliferative disease (RALD), and iTTP as an initial manifestation of systemic lupus erythematosus (SLE). The research emphasizes the importance of early ADAMTS13 testing in children with unexplained hemolysis or thrombocytopenia and highlights the need for personalized treatment approaches that consider each patient's unique clinical situation. [Extracted from the article]

A recent study conducted in Guiyang, People's Republic of China, focused on the perioperative blood management of a patient with coagulation factor V deficiency. The researchers explored the use of cryoprecipitated antihemophilic factor and fresh frozen plasma (FFP) to elevate factor V levels. The study found that cryoprecipitate and FFP were effective in supplementing coagulation factors, and the Thromboelastography (TEG) test was better than other coagulation function tests in assessing clotting status. The research emphasizes the importance of pre-transfusion and post-transfusion evaluations in combination with laboratory investigations and clinical manifestations for patients with factor V deficiency. [Extracted from the article]

A recent report from the University of California Irvine discusses a case of acquired factor XI deficiency associated with lupus anticoagulant. The report highlights the importance of recognizing factor assay interference in the presence of a known lupus anticoagulant inhibitor. The patient in the case study had a positive lupus anticoagulant and inconsistent factor XI activity results, which emphasizes the need for strategies to mitigate potentially erroneous results. This research has been peer-reviewed and published in the journal Blood Coagulation & Fibrinolysis. [Extracted from the article]

Researchers from the University of Liverpool have conducted a study on thrombocytopenic purpura, a blood disorder characterized by low platelet count. They compared the use of the automated HemosIL AcuStar(R) ADAMTS13 assay with the traditional ELISA method for diagnosing severe ADAMTS13 deficiency, a key factor in acute TTP. The study found that the AcuStar(R) assay showed good correlation with the ELISA assay when acute TTP was strongly suspected. However, caution should be exercised when interpreting ADAMTS13 activity using the AcuStar(R) assay in cases with low clinical suspicion of acute TTP. The researchers recommend incorporating robust ADAMTS13 testing algorithms into diagnostic pathways for accurate interpretation. [Extracted from the article]

A recent study conducted in Rome, Italy, examined the predictive value of the Sepsis-induced Coagulopathy (SIC) score for in-hospital mortality and complications in emergency department (ED) patients with sepsis. The study found that a positive SIC score at ED admission was an independent predictor of in-hospital mortality, as well as the development of disseminated intravascular coagulation (DIC), bleeding, thrombosis, organ injury, and the need for blood component transfusion. The researchers concluded that the SIC score is an early predictor of mortality and severe coagulopathy-related complications in ED patients with sepsis. [Extracted from the article]

Researchers at Osaka General Medical Center in Japan have developed a machine learning model for the early and accurate prediction of overt disseminated intravascular coagulation (DIC) before its progression to an overt stage. The study included adult septic patients without overt DIC, and the model was constructed using the Light Gradient Boosted Machine method. The model exhibited higher prediction accuracy compared to conventional DIC scoring systems. This research provides valuable insights into the development of anticoagulant therapies for sepsis in patients with DIC. [Extracted from the article]

A recent study conducted by Johns Hopkins University explores the efficacy of emicizumab therapy in two adult patients with Type 3 von Willebrand Disease (T3VWD). T3VWD is a rare inherited bleeding disorder caused by the absence of von Willebrand factor (VWF). The traditional treatment for T3VWD has been VWF concentrates, but their effectiveness may be limited due to the development of alloantibodies. The study found that emicizumab prophylaxis resulted in a significant reduction in bleeding episodes and improved quality of life for the patients. However, further research is needed to determine the long-term efficacy and safety profile of emicizumab for this patient population. [Extracted from the article]

A study conducted by the University of Health Sciences Turkey aimed to evaluate the impact of eltrombopag therapy on patients diagnosed with immune thrombocytopenia (ITP) based on the line of treatment. The retrospective study included 51 patients who received eltrombopag at different centers. The results showed that the choice of eltrombopag in the second or third line of treatment did not significantly affect the treatment response. The study suggests that the earlier line choice of eltrombopag, duration, and possibility of sustained response should be considered in long-term follow-up. [Extracted from the article]

A study conducted by researchers from Iwate Medical University in Morioka, Japan, highlights the case of a 37-year-old woman with severe acute liver injury caused by autoimmune hepatitis. Despite treatment with prednisolone, her prothrombin time (PT) did not return to normal levels. Further examination revealed that she had low factor VII activity, indicating a diagnosis of factor VII deficiency. The researchers suggest that altered coagulopathy should be considered in cases of liver injury with abnormal PT. This research has been peer-reviewed and published in Internal Medicine. [Extracted from the article]

A recent report from the University Medical Center Utrecht in the Netherlands discusses new research on von Willebrand disease (VWD) and carriers of hemophilia. The study found that the incidence of severe primary postpartum hemorrhage (PPH) in Dutch women with VWD and hemophilia carriers was 8%, compared to 4.5% in the general population. The research also found that the risk of severe primary PPH in women with VWD and hemophilia carriers remained stable and comparable to the increasing prevalence in the general population. Further research is needed to determine the optimal pregnancy management strategy for safe delivery in these individuals. [Extracted from the article]

A recent study conducted by Zhejiang University in Hangzhou, China examined the association between immune thrombocytopenic purpura (ITP) medication use and the risk of depression. The study analyzed data from the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2018, including 17,299 participants. The researchers found no significant association between ITP medication use and an increased risk of depression after adjusting for demographic and health-related variables. The study suggests that ITP medication use does not independently increase the risk of depression. This finding is important for guiding clinical decisions and managing patient expectations regarding ITP treatment and its psychological impacts. [Extracted from the article]

The article discusses research by Kirollos Salah Kamel and colleagues, reported in the Haemophilia issue on August 22, 2024. The study examines the diagnosis and management of Factor XI alloinhibitors in patients with congenital Factor XI deficiency, focusing on the prevalence and impact of inhibitors, especially in patients with severe deficiency and specific genotypes.

The article discusses research by Houmei Feng and colleagues from Southern Medical University, reported in the Thrombosis Journal issue on August 22, 2024. Topics include the impact of frozen storage conditions on the stability of antithrombin, protein C, and protein S activity assays, the finding that antithrombin and protein C remain stable under various freezing conditions, and the significant reduction in protein S activity, which could lead to overdiagnosis of protein S deficiency.

The article offers information on the identification of human leukocyte antigen (HLA) alleles involved in immune thrombotic thrombocytopenic purpura (iTTP) in Turkish patients. Topics discussed include the association between specific HLA alleles and iTTP susceptibility or protection; the study's methodology involving comparisons with healthy controls; and the findings that certain HLA allele pairs are linked to increased or decreased risk of iTTP.

The article offers information on how postoperative anticoagulation affects outcomes in patients with Von Willebrand Disease undergoing total hip arthroplasty. Topics discussed include the increased risk of venous thromboembolism and hematoma associated with different anticoagulation strategies; the overall impact on 90-day adverse events; and the lack of difference in 5-year revision-free survival.

The article offers information on the relationship between elevated lactate levels and the development of disseminated intravascular coagulation (DIC) in severe trauma patients. Topics discussed include lactate as a predictive factor for DIC; its association with increased mortality; and its effectiveness in risk assessment for DIC.

A 65-year-old woman developed a blood coagulation disorder while being treated with cefmenoxime for acute pancreatitis. The woman had a history of chronic renal failure, type-2 diabetes, and hypertension. She started experiencing multiple ecchymoses and bleeding, which prompted laboratory tests revealing abnormalities in her coagulation function. The blood coagulation disorder was attributed to cefmenoxime, and the medication was discontinued. The woman was then treated with amoxicillin and clavulanic-acid, along with phytomenadione. Her symptoms improved, and she was transferred to a higher-level hospital for further treatment. [Extracted from the article]

A meta-analysis conducted by researchers at the Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University in Jiangsu, China compared the efficacy and safety of two different therapeutic schedules for the treatment of Henoch-Schonlein purpura nephritis (HSPN) in children. The study found that glucocorticoids combined with mycophenolate mofetil (MMF) had a higher complete remission rate and lower incidence of adverse effects compared to glucocorticoids combined with cyclophosphamide (CTX). The analysis included ten studies involving 675 patients. The findings suggest that MMF may be a more effective and safer treatment option for HSPN in children. [Extracted from the article]

A patent application titled "Anti-Inflammatory, Non-Fucosylated Immunoglobulin Preparation And Production Method Therefor" has been published online. The inventors aim to develop a new therapeutic drug for inflammatory diseases, such as autoimmune diseases. The invention involves an afucosylated immunoglobulin preparation made from human serum IgG antibodies, which have a specific glycan bound to the Fc region. The patent application provides details on the method of producing this preparation and its potential effects in treating autoimmune diseases. [Extracted from the article]

A new report discusses research conducted at Chengdu University of Traditional Chinese Medicine on the link between gut microbiota and autoimmune diseases, specifically Henoch-Schönlein purpura (HSP) and immune thrombocytopenic purpura (ITP). The study utilized large-scale genetic data and Mendelian randomization to investigate the bidirectional causality between gut microbiota and these diseases. The research identified 23 bacterial taxa associated with HSP and ITP, with family Alcaligenaceae significantly associated with ITP as a risk factor and family Bacteroidales S24 7group significantly associated with ITP as a protective factor. The study concludes that further research is needed to understand the underlying mechanisms and develop targeted therapeutic interventions for these autoimmune diseases. [Extracted from the article]

Researchers at the University of Freiburg Medical Center have conducted a study on intracranial aneurysms and Glanzmann Thrombasthenia (GT), an inherited platelet disorder. GT is caused by defects in platelet integrin a [IIb] b [3] (GPIIb/IIIa), which is essential for fibrinogen binding. The study focuses on a 40-year-old female patient with extensive bleeding complications and platelet antibody formation, who was diagnosed with GT and also found to have bilateral para-ophthalmic aneurysms. The research highlights the challenges in treating patients with rare platelet bleeding disorders and emphasizes the importance of specialized medical care for these individuals. [Extracted from the article]

A recent study conducted by the Department of Hematologic Oncology and Blood Disorders examined the effectiveness of fostamatinib, a spleen tyrosine kinase inhibitor, in the treatment of chronic immune thrombocytopenia (ITP). The study included 31 patients who had previously received multiple lines of therapy. The results showed that 32% of patients achieved a durable response, with most responders maintaining their response at 24 months. Subgroup analysis revealed that patients who had received two to three prior lines of therapy, splenectomized patients, and those who had not received prior rituximab had higher rates of durable responses. However, 13% of patients discontinued fostamatinib due to adverse events. Overall, the study suggests that fostamatinib therapy can lead to a durable response in a third of heavily pretreated ITP patients. [Extracted from the article]

This document provides information about a clinical trial conducted by Sheffield Hallam University. The trial, with the identifier NCT06508424, aims to investigate the effects of consuming PulseOn enriched crackers for breakfast on post-prandial glycaemic response and markers of appetite. The study will recruit healthy individuals with no underlying metabolic disease and will analyze the acceptability of the crackers. Led by Caroline E Millman, PhD, the trial will also examine factors such as starch digestibility, glycemic response, and gut hormones. Further details about the trial, including eligibility criteria and contact information, are provided. [Extracted from the article]

Researchers from BioMarin Pharmaceutical Inc. have conducted a phase 3 study on valoctocogene roxaparvovec, a gene therapy for the treatment of hemophilia A. The study found that no inhibitors were detected following the administration of the therapy, and immune responses were primarily directed towards the AAV5 capsid. FVIII-specific cellular immune responses were less frequent and showed no association with safety or efficacy parameters. This research provides valuable insights into the immunogenicity outcomes of gene therapy for hemophilia A. [Extracted from the article]

Researchers at Baylor University College of Medicine have conducted a study on Type 3 von Willebrand Disease (VWD), a rare inherited blood coagulation disorder. The study found that von Willebrand factor (VWF) directly influences fibrin polymerization and the structure of fibrin clots. The researchers discovered that VWF contains an additional binding site for fibrin in the A2 domain, which plays a role in the incorporation of VWF into the fibrin matrix. The study used various techniques such as confocal microscopy and scanning electron microscopy to analyze the effects of VWF on fibrin formation and clot structure. This research provides valuable insights into the mechanisms underlying Type 3 VWD and may contribute to the development of new treatments for this condition. [Extracted from the article]

A recent study conducted in Babylon, Iraq, focused on the detection of the intron 22 inversion mutation in Iraqi patients with hemophilia A. The research involved 80 patients with hemophilia A, with genetic analysis being done using real-time thermal cyclic quantitative PCR (qPCR). The study found that the inversion 22 mutation was detected in 83.7% of the patients, indicating its significance as a major genetic transformation in severe hemophilia A. The results suggest that qPCR is a fast and effective method for detecting this mutation, which is considered an important risk factor for inhibitor production. [Extracted from the article]

A recent report from the University of Kentucky discusses new research findings on Factor X Deficiency, a rare bleeding disorder. The study describes a murine model of coagulation factor X deficiency and evaluates fitusiran as a potential therapeutic option. Factor X Deficiency is divided into two subtypes, with type I characterized by low FX protein and activity, and type II characterized by normal protein concentration but reduced activity. The current treatment options for this disorder are limited and primarily consist of blood products. Effective treatment options are crucial, especially for patients at risk of intracranial hemorrhage. [Extracted from the article]

A recent report from the Department of Oral and Maxillofacial Surgery discusses a case of unexpected massive bleeding during surgery for Crouzon syndrome, a rare genetic disorder affecting craniofacial structures. The patient, a 14-year-old female, underwent the modified LeFort III osteotomy and experienced complications including dysrhythmia, hypothermia, and cyanosis. Post-surgery, coagulation tests suggested a diagnosis of von Willebrand disease subtype 1. The research highlights the importance of vigilant monitoring for postoperative complications and the use of appropriate management strategies for patients with craniosynostosis syndromes like Crouzon syndrome. [Extracted from the article]

A recent study conducted at the University of North Texas aimed to characterize zebrafish coagulation cofactors fviii and fv mutants and determine if they exhibit similarities to classical hemophilia A and factor V deficiency in humans. The researchers used zebrafish embryos from fviii and fv mutants and performed various assays to assess their coagulation abilities. The results showed that the mutants displayed prolonged time to occlusion after injury and exhibited bleeding and delayed fibrin formation. These zebrafish models could be valuable for studying and developing drugs to reverse the phenotype and identifying compensatory factors for these deficiencies. [Extracted from the article]

In a single-center retrospective study, an elderly patient with chronic consumptive coagulopathy due to aortic disease and chronic liver failure was treated with tranexamic-acid. However, the patient experienced worsening bleeding symptoms, indicating a lack of efficacy of tranexamic-acid. The study highlights the need for further research on the effectiveness of tranexamic-acid in treating consumptive coagulopathy. [Extracted from the article]

A case report published in Reactions Weekly describes the experience of a young girl who developed lupus anticoagulant hypoprothrombinaemia syndrome (LAHPS) and systemic lupus erythematosus (SLE). The girl initially responded well to treatment with prednisone and hydroxychloroquine, but experienced a rebound effect and lack of efficacy when her prednisone dose was reduced and rituximab was introduced. She required higher doses of prednisone and additional treatments, including mycophenolate-mofetil and cyclophosphamide. Eventually, she developed lupus nephritis and was given methylprednisolone. At the time of the report, her prothrombin levels had normalized and she remained on a treatment regimen. [Extracted from the article]

A 73-year-old man developed thrombocytopenia while being treated with amiodarone for chronic atrial fibrillation. He had a history of arterial hypertension and chronic atrial fibrillation and had previously experienced haematuria after receiving low molecular weight heparin for acute pulmonary embolism. After starting amiodarone, he was hospitalized with severe uncontrolled bleeding and haemodynamic instability. The man's platelet count was low, and further investigation revealed platelet function and coagulation disorders. Amiodarone was discontinued and replaced with esmolol, which resulted in an increase in platelet count and the cessation of haematuria within two days. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the formation of anomalous amyloid structures called fibrinaloid microclots in the presence of inflammatory molecules in the blood. Proteomic analysis of these microclots reveals the presence of specific proteins with high amyloidogenic tendencies, suggesting their integration into amyloid structures. The study highlights the role of cross-seeding in fibrinaloid microclot formation and emphasizes the need for further research into their structural properties and implications in thrombotic and amyloid diseases. These findings have the potential to inform the development of diagnostic and therapeutic strategies for blood clotting disorders. [Extracted from the article]

Researchers at Iran University of Medical Sciences have detailed a novel approach to treating Melkersson-Rosenthal syndrome (MRS), a rare neuro-mucocutaneous disorder characterized by orofacial swelling, recurrent facial palsy, and fissured tongue. The researchers report a case study of a 30-year-old female patient with MRS who underwent endoscopic trans-canal facial nerve decompression after systemic steroids failed to improve her condition. The procedure was found to be safe, minimally invasive, and effective, with shorter recovery time compared to other methods. This research provides valuable insights into the management of MRS and offers a potential treatment option for patients with facial paralysis. [Extracted from the article]